{"source_content":"公司报告|首次覆盖报告请务必阅读正文之后的信息披露和免责申明1爱美客（300896）证券研究报告2020年09月30日投资评级行业医药生物/医疗器械6个月评级买入（首次评级）当前价格342.4元目标价格431.2元基本数据A股总股本(百万股)120.20流通A股股本(百万股)26.01A股总市值(百万元)41,156.48流通A股市值(百万元)8,904.59每股净资产(元)8.96资产负债率(%)7.21一年内最高/最低(元)366.20/311.00作者刘章明分析师SAC执业证书编号：S1110516060001liuzhangming@tfzq.com郑薇分析师SAC执业证书编号：S1110517110003zhengwei@tfzq.com方心诣联系人fangxinyi@tfzq.com资料来源：贝格数据相关报告股价走势差异化铸就壁垒，专业奠定医美龙头地位医美行业：后起之秀跃升医美大国，渗透率提升市场空间总览：我国医美行业起步较晚，但发展迅速，2014-2018年复合增长23.6%，2017年医美项目数超越巴西成为全球医美第二大国家。分类：高频低价的非手术类医美项目由于无需手术，风险小且效果可逆，近几年在我国收入增长迅速，2014-2018年收入CAGR约为25.7%，收入占比由2014年的28%提升至2018年的41%。消费者画像：年轻女性是医美消费的主力，占比约90%，整形目的由以工作需要为主转变为以取悦自己为主，玻尿酸是最受欢迎的入门级医美项目，非手术注射型医美项目占比约57.04%，玻尿酸占注射型医美的比重约66.59%。行业发展：伴随着女性医美需求提升、医美技术进步和政策逐步完善，医美产业红利期到来。随着医美年龄圈层扩大，我国医美渗透率有望提升。根据Frost&Sullivan预测，2021年我国将成为全球最大的医美服务市场，我国医美行业市场空间预计超过9000亿元。聚焦医美透明质酸业务，高毛利搭配高经营现金流爱美客聚焦上游终端产品销售领域，成为医疗美容透明质酸龙头，国内销售份额占比不断提高，公司在2018年医美透明质酸领域国内品牌中销售占比第一。聚焦代理专业化，高毛利率彰显业务优势，2017年至2019年，公司的综合毛利率从86.15%不断提升至92.63%，现金利润比保持在1以上。差异化战略满足个性需求，颈纹细分市场一枝独秀爱美客产品线市场定位精准，公司玻尿酸产品大多带有功效性，场景区分满足消费者多样化需求。公司的代表产品嗨体是市场唯一获批颈纹改善三类医械产品，独家供给保证高溢价高粘性，在同行公司玻尿酸单价下降的情况下，公司由于差异化定位仍能保持量价齐升。伴随着女性医美需求提升、医美技术进步和政策逐步完善，医美产业红利期到来。公司聚焦医美透明质酸业务，高毛利搭配高经营现金流，差异化战略满足个性需求，颈纹细分市场一枝独秀。综合预计公司2020-2022年净利润3.98/6.15/9.42亿元，对应2020/2021/2022年PE分别为103/67/44倍，对标行业龙头华熙生物，考虑到新股溢价和公司的扩张空间与高增速，给予公司2022年55倍PE，对应目标价431.2元/股，目标市值519亿元，首次覆盖，给予买入评级。风险提示：行业竞争加剧风险、产业结构单一风险、税收优惠变化风险财务数据和估值201820192020E2021E2022E营业收入(百万元)321.01557.72720.801,132.061,754.43增长率(%)44.2873.7429.2457.0554.98EBITDA(百万元)181.49404.86450.34698.771,070.62净利润(百万元)122.85305.52397.90615.48942.45增长率(%)49.47148.6830.2454.6853.12EPS(元/股)1.022.543.315.127.84市盈率(P/E)335.00134.71103.4366.8743.67市净率(P/B)103.3062.4637.8624.1715.56市销率(P/S)128.2173.7957.1036.3623.46EV/EBITDA0.000.0089.3356.8036.17资料来源：wind，天风证券研究所-1%17%35%53%71%89%107%125%2019-092020-012020-05爱美客医疗器械创业板指公司报告|首次覆盖报告请务必阅读正文之后的信息披露和免责申明2内容目录1.医美赛道领先者，研发壁垒铸就市场地位..............................................................................42.后起之秀跃升医美大国，渗透率提升市场空间......................................................................62.1.后起之秀，跃升医美大国............................................................................................................62.2.“高频低价”轻医美迎风而上，进口品牌主导玻尿酸市场.........................................72.3.医美年龄圈层扩大，渗透率提升市场空间............................................................................93.核心竞争力：聚焦带来专业化，差异化战略培育个性需求...............................................103.1.聚焦医美透明质酸业务，高毛利搭配高经营现金流.......................................................103.2.差异化战略满足个性需求，颈纹细分市场一枝独秀.......................................................134.高毛利率/净利率行业领先，营收步入高增轨道...................................................................165.盈利预测与估值..........................................................................................................................206.风险提示.......................................................................................................................................21图表目录图1：爱美客发展历程...................................................................................................................................4图2：爱美客主要产品...................................................................................................................................4图3：爱美客股权结构...................................................................................................................................5图4：爱美客主营收入构成占比.................................................................................................................5图5：爱美客服务解决方案..........................................................................................................................5图6：2019年直销经销销售占比...............................................................................................................6图7：2017-2019年直销经销销售收入（亿元）及增速（%）.......................................................6图8：2014-2018年美国医美消费额........................................................................................................6图9：美国、中国、巴西位列医美手术项目数排名前三（2017）................................................6图10：中国医美行业发展历程...................................................................................................................7图11：中国手术类医美和非手术类医美收入及增速（十亿人民币）.........................................8图12：中国医美行业非手术类占比..........................................................................................................8图13：中日美三国医美总疗程分布..........................................................................................................8图14：中国注射医美分布............................................................................................................................8图15：进口品牌主导玻尿酸市场..............................................................................................................9图16：与美国相比，我国医美消费更加年轻化（2017年）..........................................................9图17：我国医美消费者年龄分布情况.....................................................................................................9图18：2018年我国医美每千人诊疗次数仅为日本的一半..............................................................9图19：分年龄端的医美渗透率.................................................................................................................9图20：医美产业链........................................................................................................................................10图21：医美行业产业链图示......................................................................................................................10图22：一只玻尿酸从生产到售出的加价情况.....................................................................................11图23：中国医疗美容透明质酸产品销售金额占比............................................................................11公司报告|首次覆盖报告请务必阅读正文之后的信息披露和免责申明3图24：2017-2019爱美客平均制造费用、人工费用........................................................................12图25：2017-2019爱美客注射器、注射针采购单价.....................................................................12图26：2017-2019爱美客透明质酸纳采购单价.................................................................................12图27：2019爱美客主要产品单位成本和平均单价........................................................................12图28：2015-2019爱美客经营现金流、营业收入、净利润..........................................................13图29：2017-2019行业内公司透明质酸纳采购单价........................................................................14图30：2017-2019行业内公司注射针采购单价..............................................................................14图31：爱美客主要产品嗨体功能特点...................................................................................................14图32：颈部皱纹严重等级症状.................................................................................................................15图33：2017-2019爱美客直销和经销渠道产品平均销售单价.....................................................15图34：2017-2019爱美客、昊海生科玻尿酸产品销量及单价.....................................................16图35：2016-2019.1-3华熙生物润百颜、润致销量及单价...........................................................16图36：2015-2019爱美客营业收入....................................................................................................17图37：2015-2019爱美客营收组成....................................................................................................17图38：爱美客不同销售模式的收入占比..............................................................................................17图39：2015-2019爱美客综合毛利率................................................................................................17图40：2015-2019爱美客主要产品毛利率....................................................................................17图41：2015-2019爱美客期间费用率................................................................................................18图42：2017-2019爱美客销售费用细分占比...............................................................................18图43：2015-2019爱美客归母净利润................................................................................................18图44：2015-2019爱美客归母净利率.............................................................................................18图45：2015-2019爱美客经营/投资活动现金流............................................................................19图46：2015-2019爱美客货币资金（亿元）...............................................................................19表1：同行业可比公司财务数据...............................................................................................................19表2：公司盈利预测......................................................................................................................................20表3：公司与华熙生物的估值对比..........................................................................................................21公司报告|首次覆盖报告请务必阅读正文之后的信息披露和免责申明41.医美赛道领先者，研发壁垒铸就市场地位爱美客专注国内生物医用软组织修复材料领域，是医美赛道领先者。公司立足于生物医疗材料的研发和转化，致力于重组蛋白和多肽等生物医药的开发，与北京大学医学院等数十家高校进行合作，建有生物可降解新材料北京市工程实验室。公司作为牵头单位参与了国家科学技术部“十三五”规划国家重点研发计划“新型颌面软硬组织修复材料研发”项目，目前拥有37项专利，其中发明专利20项，形成了多组分复合仿基质水凝胶技术、固液渐变互穿交联技术、水密型微球悬浮制备技术、组织液仿生技术等核心技术体系。公司自2004年成立以来，坚持产、学、研、医一体化的研发模式，是首家取得国家药监局批准用于面部软组织修复的注射用透明质酸钠医疗器械产品注册证书的国内企业，并不断推出自主研发的新产品上市。公司主要产品有自主研发的逸美、宝尼达、爱芙莱、嗨体、逸美一加一、爱美飞等等。图1：爱美客发展历程资料来源：公司官网，天风证券研究所图2：爱美客主要产品资料来源：招股说明书，天风证券研究所董事会成员学历背景突出，大多数为世界名校硕士出身。简军女士为公司的控股股东、实际控制人，在本次公开发行股份之后直接持有公司30.96%股份，并通过丹瑞投资、客至上投资及知行军投资间接持有公司15.54%的股份，直接或间接合计持有公司的股份比例为46.5%。其弟弟简勇为公司第九大股东，担任董事、董事会秘书。董事会各成员均曾在各大公司任重要职位，深厚的学历背景及丰富的经验使得公司管理层决策能力强、眼光独到，领先且具有自主知识产权的核心技术使得爱美客能够在医美行业具备核心竞争力。公司报告|首次覆盖报告请务必阅读正文之后的信息披露和免责申明5图3：爱美客股权结构资料来源：招股说明书，天风证券研究所图4：爱美客主营收入构成占比资料来源：Wind，天风证券研究所公司拥有一套完整的研发管控体系，共有研发人员及技术人员72名，占总员工人数22.86%。公司研发及生产技术人员涵盖生物工程、高分子化学与物理、制药工程等专业。公司以市场及临床需求为导向确定研发项目，通过不断丰富在研产品线，确保各个研发阶段的产品储备，以此保证公司实现可持续的长期发展。在销售方面，公司注重产品维护，产品梯队合理、产品线齐全。公司五款产品在配方组份、注射部位、注射体验等方面有所不同，能够满足多个细分市场的消费需求。在售后持续服务方面，公司为下游医疗机构提供三阶段优质服务。在产品上市前期准备阶段、产品发布阶段、持续销售阶段，公司都提供多种针对性服务。图5：爱美客服务解决方案29.50%72.27%71.62%59.26%15.34%23.36%30.58%24.74%9.58%7.10%10.48%0.23%4.75%68.41%41.90%16.96%5.02%1.74%1.01%3.86%1.19%0.69%0.420.00%10.00%20.00%30.00%40.00%50.00%60.00%70.00%80.00%90.00%100.00%20142015201620172018爱芙莱嗨体宝尼达逸美一加一逸美其他主营业务公司报告|首次覆盖报告请务必阅读正文之后的信息披露和免责申明6资料来源：招股说明书，天风证券研究所在销售渠道结构上，公司采取直销为主，经销为辅的销售模式。这种销售模式能够使得公司更多地参与到医疗美容机构的产品推广和终端销售，可以更好地提高产品与服务质量。图6：2019年直销经销销售占比图7：2017-2019年直销经销销售收入（亿元）及增速（%）资料来源：招股说明书，天风证券研究所资料来源：招股说明书，天风证券研究所2.后起之秀跃升医美大国，渗透率提升市场空间2.1.后起之秀，跃升医美大国医美即“医疗”+“美容”的结合，医是手段，美是目的，本质是用医疗手段进行美容，指运用药物、手术、医疗器械等医学技术对人的容貌和各部位形态进行修复与再塑的美容方式，具有一定创伤性和侵入性。国际上近代医疗美容起源于20世纪初期，世界大战推动了医美行业的发展，以美韩为首的发达国家已培养出成熟的服务体系和监督机制。据国际整形美容医学会统计，全球医疗美容服务疗程数2011-2017年的年复合增长率为8.04%，国际医美行业处于稳定发展阶段。图8：2014-2018年美国医美消费额图9：美国、中国、巴西位列医美手术项目数排名前三（2017）64.08%35.92%直销模式经销模式1.692.303.570.540.912.0036.27%55.46%69.39%119.84%0.00%20.00%40.00%60.00%80.00%100.00%120.00%140.00%0.001.002.003.004.00201720182019直销模式（亿元）经销模式（亿元）直销模式增速经销模式增速公司报告|首次覆盖报告请务必阅读正文之后的信息披露和免责申明7资料来源：ASPS，天风证券研究所资料来源：更美研究院、ISAPS，天风证券研究所我国医美行业起步较晚，但发展迅速，医美市场从以矫正治疗为主的单一市场逐渐发展成揽括医疗治疗及美容美观的多样化市场。我国医美从建国后传入，至改革开放之后开始兴起，目前已进入快速发展阶段。20世纪六七十年代我国整形外科仅开展以畸形矫正为主的手术，20世纪90年代各大医院陆续设立医疗美容科，直至21世纪初中国医美行业才逐渐成型，并与国际接轨，成为我国经济中一个不可缺少的组成部分。即便起步较晚，由于国际上的医美技术已经成型，加之消费者观念的变化，中国的医疗美容业发展非常迅速。图10：中国医美行业发展历程资料来源：中国整形美容协会，新氧，天风证券研究所我国医美行业进入快速发展阶段，2014-2018年复合增长23.6%，2017年医美项目数超越美国成为全球医美第二大国家。根据Frost&Sullivan数据，2014-2018年复合增长23.6%，2018年我国医美行业规模为1217亿元，同比增长22.6%，从医美项目数来看，2017年中国医美项目数达1020万例，超过巴西成为仅次于美国的全球医美第二大国。2.2.“高频低价”轻医美迎风而上，进口品牌主导玻尿酸市场20世纪90年代以来，医美技术迅速发展，肉毒素、激光脱毛、玻尿酸等医美新科技陆续诞生。1945年，二战的爆发催生了鼻部整型，20世纪60-90年代，硅胶假体隆胸、脂肪抽吸术、非手术整形依次产生。90年代以来，医美技术迅速发展，肉毒素、激光脱毛、玻尿酸等医美新科技陆续诞生。按照是否进行手术，医疗美容可分为手术类与非手术类。手术类项目旨在从根本上改变/改善眼、鼻、胸等面部及身体其他部位的外观，非手术类项目主要包括注射及激光疗法等微整形术，可分为注射填充类、无创年轻化、激光美容等。一129.28133.83164.39167.60165.072.34%3.52%22.83%1.95%-1.51%-5%0%5%10%15%20%25%05010015020020142015201620172018美国医美消费总额（亿美元）yoy960102016600500100015002000巴西中国美国（万人）公司报告|首次覆盖报告请务必阅读正文之后的信息披露和免责申明8般经卫生部门行政许可设立的医疗美容机构均可开展上述两类项目。非手术类医美项目（轻医美）由于无需手术，风险小且效果可逆，具有高频低价的优势，近几年在我国收入增长迅速。2014-2018年非手术类医美项目收入CAGR约为25.6%，而2014-2018年手术类医美项目收入CAGR约为22.3%。非手术类医美项目收入占比由2014年的38%提升至2018年的41%，非手术案例数占比预计由2011年的59%提升至2018年的71%。目前玻尿酸注射、肉毒素注射、光子嫩肤、自体脂肪填充、超声刀、激光脱毛等已成为最受消费者欢迎的医美项目。根据Frost&Sullivan预测，2023年非手术类医美项目收入预计达到161亿元，收入占比将达到45%。图11：中国手术类医美和非手术类医美收入及增速（十亿人民币）图12：中国医美行业非手术类占比资料来源：Frost&Sullivan，天风证券研究所资料来源：ISAPS，36氪，Frost&Sullivan，德勤，天风证券研究所2018年我国非手术注射型医美项目占比最大（57.04%），其中玻尿酸占注射型医美比重最大（66.59%）。在所有医美项目中，非手术类的注射型医美占据医美消费总次数的57.04%，远高于美国的44.17%和日本的42.08%。而注射医美中，玻尿酸和肉毒素占比分别为66.59%和32.67%，2018年增速分别为53.11%和90.56%。图13：中日美三国医美总疗程分布图14：中国注射医美分布资料来源：ISAPS，新氧大数据，天风证券研究所资料来源：2019新氧白皮书，天风证券研究所进口品牌主导注射医美中玻尿酸市场，国产品牌近年来增速较快，市场占有率有望进一步提升。根据Frost&Sullivan，2014-2018年之间，中国医疗美容注射产品市场中，国产品牌销售收入增速较快，复合增长率为32.2%，高于同期进口品牌的18.7%。从销售收入占比来看，进口品牌由于单价较高，占据市场主导地位，2018年中国排名前三的本土企业爱美客生物、昊海生物、华熙生物占比总计仅为23.4%。但随着本土产品品类增多，质量提升，技术革新，本土品牌的市场占有率有望进一步提升。323947597289109133164200202531405064801011281610%10%20%30%40%0100200300手术类医美服务收入非手术类医美服务收入手术类医美服务yoy非手术类医美服务yoy59%61%62%65%66%68%70%71%38%39%40%40%41%0%10%20%30%40%50%60%70%80%非手术类案例数占比非手术类总收入占比20.55%16.09%9.75%14.60%11.44%11.89%57.04%42.08%44.17%4.99%13.53%10.41%5.30%26.85%9.18%0%20%40%60%80%100%中国日本美国手术之头面部手术之胸部手术之身体与四肢非手术之注射非手术之面部年轻化非手术之其他66.59%32.67%0.74%玻尿酸肉毒注射其他公司报告|首次覆盖报告请务必阅读正文之后的信息披露和免责申明9图15：进口品牌主导玻尿酸市场资料来源：Frost&Sullivan，天风证券研究所2.3.医美年龄圈层扩大，渗透率提升市场空间相较于国外，我国医美消费者更加年轻化，年龄层有向上提升的趋势。我国医美行业消费者以年轻消费者为主，平均年龄为24.45岁，2019年25岁以下的医美消费者占比约54%，与美国等医美消费大国相比，我国医美消费者更加年轻化。整体而言，医美年龄层有向上提升的趋势，2019年30岁以上医美消费者占比已从2016年的13%提升至19%。年轻女性是医美消费的主力，占比约90%，但医美行业男性消费者客单价是女性消费者的2.75倍。从性别上看，2019年医美女性消费者数量占医美消费者总数的88.88%，女性消费者数量是男性消费者的8倍，但男性消费者平均客单价更高，2018年医美行业男性消费者平均客单价（7025元）是女性消费者平均客单价（2551元）的2.75倍。图16：与美国相比，我国医美消费更加年轻化（2017年）图17：我国医美消费者年龄分布情况资料来源：新氧大数据，天风证券研究所资料来源：新氧大数据，天风证券研究所人均可支配收入提升、女性崛起和社会包容度提升是促进医美需求的因素，伴随着医美年龄圈层扩大，我国医美渗透率有望提升。目前我国医美渗透率偏低，2018年我国医美诊疗次数为14.8次/千人，仅为日本的一半，不及韩国的五分之一，与美国、巴西等国家相比存在较大的提升空间。而从不同年龄段的渗透率来看，20-25岁的消费者中的医美渗透率约7.18%，远高于全国1.48%的渗透率，逼近韩国8.62%的渗透率，随着目前为医美主力的年轻女性的年龄提升，医美年龄圈层有望扩大，我国整体医美渗透率有望提升。图18：2018年我国医美每千人诊疗次数仅为日本的一半图19：分年龄端的医美渗透率26.80%26.40%25.50%16.40%17.90%19.40%12.70%13.40%13.20%18.40%14.90%12.20%5.70%7.00%8.60%7.80%8.20%7.20%7%5.40%6.60%5.20%6.80%7.20%0.00%20.00%40.00%60.00%80.00%100.00%201620172018韩国LG美国Allergan韩国Humedix瑞典Q-Med爱美客生物昊海生物华熙生物其他53%43%4%10%16%74%0%20%40%60%80%25岁以下26-35岁36岁以上中国美国70%17%13%53%25%23%59%23%18%54%27%19%0%20%40%60%80%25岁以下26-30岁30岁以上20162017年2018年2019年公司报告|首次覆盖报告请务必阅读正文之后的信息披露和免责申明10资料来源：Frost&Sullivan，天风证券研究所资料来源：新氧大数据、国家统计局，天风证券研究所根据Frost&Sullivan预测，2021年我国将成为全球最大的医美服务市场，我国医美行业市场空间预计超过9000亿元。根据Frost&Sullivan预测，2021年我国将成为全球最大的医美服务市场，2023年我国医美行业规模有望达到3601亿元。未来伴随着医美消费渗透率的持续提升，医美行业的发展空间有望保持继续增长。2018年我国医美消费水平为5893元/次，对标日本、巴西、美国、韩国平均52.85次/千人的诊疗次数，以及美国2018年12224元/次的消费水平，我国医美行业市场空间预计超过9000亿元。3.核心竞争力：聚焦带来专业化，差异化战略培育个性需求3.1.聚焦医美透明质酸业务，高毛利搭配高经营现金流医美产业链上下游剖析，上游占据利润大头。医疗美容产业链格局以上游医疗美容耗材生产商和器械设备制造商为起点，中游为医疗美容机构，包括公立医院整形外科、皮肤科和非公立医疗美容机构，下游为广大终端消费者。医美行业交易额因为消费场景限制主要发生在下游，但下游因受销售费用的侵蚀，盈利水平不乐观。而上游因为产业和格局相对集中，龙头公司毛利率水平高，并且为资金和技术密集型行业特征，对于公司的技术储备、研发支持和工艺积累要求高，并且行业具有专利保护和审核批准等特点，行业整体的门槛和壁垒较高，从而获取产业链条的大部分利润。图20：医美产业链资料来源：清科研究中心，天风证券研究所图21：医美行业产业链图示86.251.946.227.114.8020406080100韩国美国巴西日本中国次/千人41488951231250251.25%7.18%4.45%2.75%0.51%0.04%0%1%2%3%4%5%6%7%8%02004006008001000医美消费者人数（万人）医美渗透率公司报告|首次覆盖报告请务必阅读正文之后的信息披露和免责申明11资料来源：Wind，天风证券研究所图22：一只玻尿酸从生产到售出的加价情况资料来源：爱美客，昊海生科，华熙生物招股说明书，天风证券研究所公司聚焦上游终端产品销售领域，成为医疗美容透明质酸龙头，国内销售份额占比不断提高。观察同行业内的其他公司，华熙生物主营业务包括医疗终端产品，功能性护肤品和原料业务，实行的是纵向发展模式，昊海生科业务包括眼科、整形美容、创面护理、骨科等板块，实行的是连横发展模式。爱美客则聚焦于医美玻尿酸业务，虽然承担了相应的业务过于集中的风险，但公司在医疗美容透明质酸产品领域却保持了持续增长的势头，根据Frost&Sullivan的数据，公司在2018年医美透明质酸领域国内品牌中销售占比达到第一。图23：中国医疗美容透明质酸产品销售金额占比80%25%33%77%32%25%80%25%33%51%22%8%41%24%-13%82%37%15%-40%-20%0%20%40%60%80%100%毛利率销费率净利率毛利率销费率净利率毛利率销费率净利率毛利率销费率净利率毛利率销费率净利率毛利率销费率净利率华熙生物昊海生科爱美客华韩整形荣恩集团新氧上游下游2017201820192020H1原材料成本出厂销售价主流平台&大型医美连锁医院折扣零售价24.72元/支417-1250元/支352.61元/支共享毛利率40%-80%毛利率92%加价14.62倍加价1.2-3.54倍原材料生产商经销商、医美机构及医美服务平台上游下游公司报告|首次覆盖报告请务必阅读正文之后的信息披露和免责申明12资料来源：Frost&Sullivan，天风证券研究所公司固定成本控制合理，上游高溢价率主导下游市场。对公司2019年的成本费率结构进行拆分，产品主要包括三部分成本：制造费用、工人工资和直接材料，前两者制造费用加上工人工资成本合计为13.27元/支。对直接材料成本进一步拆分：注射器、一次性无菌注射针头和透明质酸纳，前两者合计成本为5.49元/支。由此在除去透明质酸纳成本之后，产品2019年的平均固定成本为18.76元/支。以2019年贡献最多销售收入的嗨体产品为例，以公司披露的单位成本24.72元/支倒算出透明质酸纳成本价大约为5.96元/支，而嗨体的平均单价达到了352.61元/支，公司以其行业的高壁垒和稀缺性展现了对于下游服务和消费机构的高定价能力。图24：2017-2019爱美客平均制造费用、人工费用图25：2017-2019爱美客注射器、注射针采购单价资料来源：招股说明书，天风证券研究所资料来源：招股说明书，天风证券研究所图26：2017-2019爱美客透明质酸纳采购单价图27：2019爱美客主要产品单位成本和平均单价5.20%6.80%7.20%7.00%5.40%6.60%7.80%8.20%7.20%5.70%7.00%8.60%18.40%14.90%12.20%12.70%13.40%13.20%16.40%17.90%19.40%26.80%26.40%25.50%0%20%40%60%80%100%201620172018其他华熙生物昊海生科爱美客瑞典Q-Med韩国Humedix美国Allergan韩国LG8.277.675.389.3410.937.89024681012201720182019制造费用（元/支）人工费用（元/支）7.094.74.583.952.810.9102468201720182019预灌封注射器（元/支）一次性使用无菌注射针（元/支）公司报告|首次覆盖报告请务必阅读正文之后的信息披露和免责申明13资料来源：招股说明书，天风证券研究所资料来源：招股说明书，天风证券研究所聚焦核心业务配合成本控制，高毛利率彰显业务优势，高效管理实现真实现金流。从2017年至2019年，公司的综合毛利率水平保持持续增长的态势，从86.15%不断提升至92.63%。公司的产品线布局细分市场以获取高溢价、消费者对待医美的观念的转变伴随消费升级趋势和公司产量销量的增长从而规模效应不断增强共同促成公司不断提升的毛利率。高利润率的背后同样是公司优秀的现金流水平。以2015年至2019年过去5年为观察窗口，公司经营活动现金净流量持续大于净利润，现金利润比保持在1以上，利润实现真金白银落袋，体现公司优秀的现金收款能力和高行业地位。公司销售商品提供劳务收到的现金也持续大于营业总收入，真实现金流和高财务治理反映公司优秀的管理能力。公司立足注射透明质酸纳业务聚焦核心项目，以行业高壁垒锁定高毛利，固定成本合理控制，实现高经营现金利润比。图28：2015-2019爱美客经营现金流、营业收入、净利润资料来源：Wind，天风证券研究所3.2.差异化战略满足个性需求，颈纹细分市场一枝独秀公司产品线市场定位精准，场景区分满足消费者多样化需求。公司主要产品逸美和宝尼达以多组分复合仿基质水凝胶技术为核心，适用于额部和鼻唇部；爱芙莱和爱美飞以固液渐变互穿交联技术为核心，适用于鼻唇沟部位；嗨体以组织液仿生技术为核心，适用于颈部区域；紧恋以恒水精准切割技术为核心，适用于鼻唇沟部位。其中嗨体和爱芙莱是公司的主打产品，2019年营收占比中嗨体为43.50%，爱芙莱39.27%，宝尼达以12.10%占比其次。140.75138.96144.14136137138139140141142143144145201720182019透明质酸纳（元/克）352.61310.832547.4924.7230.4132.34050010001500200025003000嗨体爱芙莱宝尼达平均单价（元）单位成本（元）1.331.672.643.675.751.121.412.223.215.580.480.550.841.353.100.180.530.771.162.980.001.002.003.004.005.006.007.0020152016201720182019单位：亿元销售商品提供劳务收到的现金营业总收入经营活动现金净流量净利润公司报告|首次覆盖报告请务必阅读正文之后的信息披露和免责申明14原料采购价格行业内差距不大，价差主要源于定制需求。在主要原材料透明质酸纳、注射器和一次性无菌注射针的采购上，公司和同行业内其他公司的采购价格不存在重大差异，根据公司招股说明书的解释，透明质酸纳的采购价格稍高于同业主要是公司采购的为高规格透明质酸纳，注射针的采购价格稍高主要是公司根据产品的性能特点，采购了特制产品。图29：2017-2019行业内公司透明质酸纳采购单价图30：2017-2019行业内公司注射针采购单价资料来源：招股说明书，天风证券研究所资料来源：招股说明书，天风证券研究所市场唯一获批颈纹改善三类医械产品，独家供给保证高溢价高粘性。公司的代表产品嗨体是目前唯一经国家药监局批准的针对颈部皱纹改善的三类医疗器械产品，填补了颈部皱纹修复领域的空白，产品核心技术获得国家发明专利。嗨体主要用于皮内真皮层注射填充，修复颈部皱纹。在受众群体上没有规定限制，年满18岁以上人士均可接受注射治疗。嗨体使用频次较高，根据临床效果和医生建议，多数客户会在注射完成后1-3个月后再次选择注射，高黏性高频次加上国内唯一获批保证客户忠诚度。图31：爱美客主要产品嗨体功能特点资料来源：新氧，天风证券研究所170.94140.75122.62154.96138.96113.83150.37144.14111.69050100150200昊海生科爱美客华熙生物元/克2017201820193.952.810.910.640.630.58012345201720182019元/支爱美客昊海生科公司报告|首次覆盖报告请务必阅读正文之后的信息披露和免责申明15发力颈纹长尾人群，市场培育之下利基终成大众需求。嗨体于2016年底推出，作为国内首款临床用于颈纹修复的复合注射材料，2017年主要立足于市场的培育和开拓，在前期开拓阶段，产品推广活动较多，以培育消费者习惯和占领消费者心智为主要目的，产品的单价较低。2018年开始产品接受度不断提高，销量保持增长势头。作为国内唯一面向颈纹修复的嗨体产品，行业发展曲线与公司发展曲线重合，从市场培育，到消费习惯养成，公司掌握唯一市场定价权。随着移动智能时代的不断发展渗透，过度使用手机引发的问题所带来的后端市场也开始进入消费者视野，对于颈部皱纹的关注度也在不断提高。图32：颈部皱纹严重等级症状资料来源：新氧，天风证券研究所独家领域锁定市场垄断格局，直销为主保持价格持续抬升。嗨体作为目前国内市场唯一获批的颈纹改善的三类医疗器械产品我国监管部门对于医疗美容行业在近几年规范力度不断加强，一款医美产品的上市需要经过实验室研究、动物实验、注册检验、临床研究和申报注册等环节，研发过程历史较长，嗨体作为目前国内市场唯一获批的颈纹改善的三类医疗器械产品，嗨体在直销渠道和经销渠道双模式下平均单价不断上升。直销模式下嗨体平均单价从2017年286.83元上升到2019年的354.19元，销量从8.57万支上升到36.08万支；经销模式下嗨体从2017年的280.44元上升到2019年的269.03元，销量从3.47万支上升到32.72万支。由于经销模式的特点，经销渠道的价格平均来看稍微低于直销渠道的价格，而公司直销渠道在2019年占比64.08%，已与超过2000家客户建立合作关系，包括中国医学科学院整形外科医院、中日友好医院等三甲公立医院等优质客户群，直销模式保证了公司对于医疗机构资源和消费者偏好的把握，有利于之后新的市场和产品的开发。图33：2017-2019爱美客直销和经销渠道产品平均销售单价公司报告|首次覆盖报告请务必阅读正文之后的信息披露和免责申明16资料来源：招股说明书，天风证券研究所玻尿酸领域公司产品保持量价齐升，不惧市场价格波动。以公司玻尿酸领域同行业内其他2家上市公司进行对比，由于公司玻尿酸产品占公司营收比几乎接近100%，其他主营业务占比仅为0.15%，以公司营收数据和销量数据算出公司产品综合的平均单价，从2017年338.59元/支稳步上升到2019年383.13元/支。选取华熙生物注射用透明质酸中销售占比最高的润百颜和润致为代表，计算出其平均售价从2016年的425.85元/ml下降到2019年前3个月的290.44元/ml。昊海生科的业务布局较广，其在财报中对各项业务进行了单独数据披露，选取其中玻尿酸的相关数据，粗略以营收数据和销量数据计算出公司玻尿酸产品的平均单价，从2017年290.55元/支下降到2019年268.65元/支，其年报中表示是受到下游医疗美容机构竞争激烈和获客成本居高不下导致玻尿酸产品持续受到降价压力。图34：2017-2019爱美客、昊海生科玻尿酸产品销量及单价图35：2016-2019.1-3华熙生物润百颜、润致销量及单价资料来源：招股说明书，天风证券研究所资料来源：招股说明书，天风证券研究所4.高毛利率/净利率行业领先，营收步入高增轨道公司营收高速增长，营收主要来自于注射类透明质酸钠的相关产品。2017/2018/2019年公司营收分别为2.22/3.21/5.58亿元，同比增速为58.09%/44.28%/73.74%。营收高速增长，近三年增速维持在40%以上。2020H1营收为2.42亿，同比增长0.72%，在上半年疫情影响下依然保持了营收的持续增长。公司营业收入主要来自爱芙莱、宝尼达、嗨体等注射类透明质酸钠相关产品的销售，上述产品销售收入占主营业务收入的比例在近三年均超过95%。公司持续研发新产品，2019年有六款主要产品，并且有多项在研产品取得阶段性的成果。286.83321.73354.19280.44305.38350.87050100150200250300350400201720182019直销平均单价（元）经销平均单价（元）338.59355.65383.13290.56285.34268.6565.7190.26145.5787.7893.2676.070.00100.00200.000.00200.00400.00600.00201720182019爱美客单价(元/支)昊海生科单价(元/支)爱美客销量(万支)昊海生科销量(万支)274537207969365447140934425.85398.06266.95290.44010020030040050001000002000003000004000002016201720182019.1-3华熙生物：销量（ml）华熙生物：单价（元/ml）公司报告|首次覆盖报告请务必阅读正文之后的信息披露和免责申明17图36：2015-2019爱美客营业收入图37：2015-2019爱美客营收组成资料来源：Wind,招股说明书，天风证券研究所资料来源：Wind,招股说明书，天风证券研究所公司采取直销和经销相结合的销售方式，直销为主，经销为辅，经销占比有逐年提升的趋势。公司直销模式下客户分为非公立医疗机构和公立医院两类，其中从非公立医疗机构取得的收入占直销收入的比例超过95%。经销模式下公司对经销商的资质、信用、规模等因素进行严格考评后，将产品销售给经销商，由经销商对产品进行分销，使产品进入各地医疗机构。近三年经销收入占比逐年提升，在2019年达到35.92%。图38：爱美客不同销售模式的收入占比资料来源：Wind,招股说明书，天风证券研究所公司综合毛利率近三年持续提升，2019年主要产品毛利率均在90%以上。2017/2018/2019/2020H1公司综合毛利率分别为86.15%/89.34%/92.63%/90.22%，毛利率持续提升并且维持在高水平。综合毛利率的上升主要是由于随着产量增加，规模效应使得主要产品的单位成本进一步下降，收入占比较大的爱芙莱和嗨体产品毛利率有所上升。2019年主要产品毛利率均在90%以上。图39：2015-2019爱美客综合毛利率图40：2015-2019爱美客主要产品毛利率1.121.412.223.215.582.4248.84%25.86%58.09%44.28%73.74%0.72%0%10%20%30%40%50%60%70%80%0.01.02.03.04.05.06.0营业收入（亿元）YoY15.34%23.36%43.50%29.50%72.27%71.62%59.26%39.27%24.74%9.58%7.10%10.48%12.10%0.23%4.75%3.73%0.87%41.90%16.96%5.02%1.74%0.373.86%1.19%0.69%0.42%0.16%0%20%40%60%80%100%120%20152016201720182019嗨体爱芙莱宝尼达逸美一加一爱美飞逸美其他85.14%89.62%75.82%71.61%64.08%14.86%10.38%24.18%28.39%35.92%0%20%40%60%80%100%120%20152016201720182019直销经销公司报告|首次覆盖报告请务必阅读正文之后的信息披露和免责申明18资料来源：Wind,招股说明书，天风证券研究所资料来源：Wind,招股说明书，天风证券研究所公司期间费用率基本稳定，2019年有所下降，销售费用中人工费占比最高。2017/2018/2019公司期间费用率分别为42.88%/43.24%/30.86%，在2019年有所下降，主要是由于销售费用率和管理费用率有所下降,2020H1期间费用率进一步下降到24.27%。销售费用中人工费占比最高，且近三年人工费占比逐年提升，主要系公司销售人员数量及奖金绩效增加所致。图41：2015-2019爱美客期间费用率图42：2017-2019爱美客销售费用细分占比资料来源：招股说明书，天风证券研究所资料来源：招股说明书，天风证券研究所公司近三年归母净利润维持较高增速，归母净利率在2019年大幅提升。2017/2018/2019年公司归母净利润分别为0.82/1.23/3.06亿元，同比增速为53.99%/49.47%/148.68%。2020H1归母净利润为1.48亿元，同比增速为14.59%，上半年疫情影响下依然保持正增长，高效的营销服务水平、精准的产品定位和较强的研发创新能力是公司高速增长的关键。2017/2018/2019/2020H1归母净利率分别为36.94%/38.27%/54.78%/60.89%，逐年提升且在2019年有较大增幅，主要由于毛利率的增长以及期间费用率的下降。图43：2015-2019爱美客归母净利润图44：2015-2019爱美客归母净利率91.31%87.19%86.15%89.34%92.63%90.22%82%84%86%88%90%92%94%84.24%87.09%90.22%98.15%98.11%98.73%27.72%27.46%37.44%20%40%60%80%100%201720182019嗨体爱芙莱宝尼达逸美一加一爱美飞逸美其他41.13%13.17%11.55%13.84%8.62%6.28%9.29%-0.35%-0.31%-0.31%-0.53%-0.31%-0.36%65.71%43.22%42.88%43.24%30.86%24.27%-20%0%20%40%60%80%销售费用率管理费用率研发费用率财务费用率期间费用率42.13%47.75%59.20%13.20%12.96%11.25%9.16%9.74%4.44%9.72%8.24%6.95%7.75%7.17%6.76%9.50%6.58%6.51%0%20%40%60%80%100%201720182019人工费会议费销售促进费差旅交通费业务招待费广告宣传费物流运输费其他公司报告|首次覆盖报告请务必阅读正文之后的信息披露和免责申明19资料来源：Wind,招股说明书，天风证券研究所资料来源：Wind,招股说明书，天风证券研究所公司经营活动现金流净额持续增长，货币资金充沛，主要由于公司营收规模的扩大所致。2017/2018/2019年公司经营活动现金流净额分别为0.84/1.35/3.1亿元，维持高速增长，主要由于销售收入增加的影响。2017/2018/2019年公司货币资金分别为2.14/2.66/5.06亿元，保持增长趋势，主要由于公司整体营收规模的扩大，货币资金充足。公司2020H1投资活动现金流相比往年流出规模较大，上半年为-3.04亿，综合公司过去年份投资活动现金流变化规律，部分原因可能是公司购买投资理财产品产生现金流出，而产品收益现金收回在上半年较少所致。图45：2015-2019爱美客经营/投资活动现金流图46：2015-2019爱美客货币资金（亿元）资料来源：Wind,招股说明书，天风证券研究所资料来源：Wind,招股说明书，天风证券研究所公司毛利率和净利率高于同行业可比公司，但营收规模和净利润处于较低水平。相较于可比公司，爱美客营业收入规模大幅低于华熙生物和昊海生科，主要由于公司产品品类较为单一。但公司毛利率和归母净利率在近三年均高于同行业可比公司，盈利能力较强，主要由于公司的产品结构所致。在透明质酸钠原料价格方面，爱美客采购价格低于昊海生科。华熙生物为透明质酸钠原料生产商，其销售单价低于爱美客和昊海生科的采购单价。表1：同行业可比公司财务数据2020H1201920182017营业收入（亿元）华熙生物9.4718.8612.638.18昊海生科4.9616.0415.5813.54可比公司平均7.2217.4514.1110.86爱美客2.425.583.212.22归母净利润（亿元）华熙生物2.675.864.242.22昊海生科0.283.714.153.72可比公司平均1.484.794.202.970.180.530.821.233.061.48-37.89%202.38%53.99%49.47%148.68%14.59%-50%0%50%100%150%200%250%0.00.51.01.52.02.53.03.5归母净利润（亿元）YoY15.79%37.93%36.94%38.27%54.78%60.89%0%10%20%30%40%50%60%70%0.480.550.841.353.101.15-0.49-0.11-0.11-0.38-0.26-3.04-4.0-3.0-2.0-1.00.01.02.03.04.0经营活动现金流（亿元）投资活动现金流（亿元）0.491.562.142.665.063.160.01.02.03.04.05.06.0公司报告|首次覆盖报告请务必阅读正文之后的信息披露和免责申明20爱美客1.483.061.230.82毛利率华熙生物79.74%79.66%79.92%75.48%昊海生科77.21%77.31%78.54%78.68%可比公司平均78.48%78.49%79.23%77.08%爱美客90.22%92.63%89.34%86.15%期间费用率华熙生物50.12%41.63%38.23%41.78%昊海生科79.95%53.80%49.32%46.78%可比公司平均65.04%47.72%43.78%44.28%爱美客24.27%30.86%43.24%42.88%归母净利率华熙生物28.19%31.06%33.56%27.17%昊海生科5.55%23.11%26.60%27.50%可比公司平均16.87%27.08%30.08%27.33%爱美客60.89%54.78%38.27%36.94%透明质酸钠（元/克）华熙生物销售单价/111.69113.83122.62昊海生科采购单价/150.37154.96170.94爱美客采购价格/144.14138.96140.75资料来源：Wind,招股说明书，天风证券研究所5.盈利预测与估值核心假设：1.公司嗨体是市场唯一获批颈纹改善三类医械产品，近几年能保持高增速，预计2020/2021/2022年嗨体销量增长60%/70%/60%;2.公司募投项目——植入医疗器械生产线二期建设项目预计三年大成后产能分别为爱芙莱127.87万支、嗨体220.87万支、逸美10.33万支、宝尼达1.64万支，考虑到已有产能，预计2022年公司产品销量能超过二期产能。3.2020年受疫情影响，预计除嗨体外其他产品销量出现下滑表2：公司盈利预测201720182019202020212022营业收入\\百万元222.49321.01557.72720.801132.061754.43YOY58%44%74%29%57%55%注射用修饰透明质酸钠凝胶（爱芙莱)收入159.35190.23218.99216.80287.48395.86YOY57%19%15%-1%33%38%注射用透明质酸钠复合溶液（嗨体）收入34.1374.97242.59407.56727.491210.54YOY120%224%68%79%66%医用含聚乙烯醇凝胶微球的透明质酸钠-羟丙基甲基纤维素凝胶（宝尼达）收入15.8033.6467.5065.4980.16102.21YOY17%113%101%-3%22%28%医用透明质酸钠-羟丙基甲基纤维素凝胶（逸美一加一）收入0.5115.2520.7922.6426.8933.28YOY2884%36%9%19%24%透明质酸钠凝胶（爱美飞）公司报告|首次覆盖报告请务必阅读正文之后的信息披露和免责申明21收入4.885.076.538.72YOY4%29%34%医用羟丙基甲基纤维素-透明质酸钠溶液（逸美）收入11.175.582.081.161.431.75YOY-53%-50%-63%-44%22%22%其他收入1.541.342.082.082.082.08YOY-8%-13%40%0%0%0%资料来源：Wind，天风证券研究所伴随着女性医美需求提升、医美技术进步和政策逐步完善，医美产业红利期到来。公司聚焦医美透明质酸业务，高毛利搭配高经营现金流，差异化战略满足个性需求，颈纹细分市场一枝独秀。综合预计公司2020-2022年净利润3.98/6.15/9.42亿元，对应2020/2021/2022年PE分别为103/67/44倍，对标行业龙头华熙生物，考虑到新股溢价和公司的扩张空间与高增速，给予公司2022年55倍PE，对应目标价431.2元/股，目标市值519亿元，首次覆盖，给予买入评级。表3：公司与华熙生物的估值对比2020E2021E2022E华熙生物净利润（百万元）6458761170增长率(%)10%36%34%市盈率（P/E)926851爱美客2020E2021E2022E净利润（百万元）398615942增长率(%)30%55%53%市盈率（P/E)1046744资料来源：Wind，天风证券研究所6.风险提示①行业竞争加剧风险公司是国内生物医院软组织修复材料领域的创新型领先企业，在国内具有一定的先发优势。但行业也面临其他市场参与者通过自主研发或者兼并收购带来的竞争，行业的竞争程度随着医疗美容市场的不断扩容而逐渐加剧，包括研发注册、工艺技术、产品质量、优秀人才等多方面的竞争。如果公司无法持续保持竞争力，经营业绩可能无法保持增长趋势。②产业结构单一风险公司以自有核心技术专注于软组织修复材料领域，给公司带来产品技术优势的同时，也使得公司面临产品结构相对单一的风险。现阶段公司产品较为集中，但果现有产品的生产、销售、市场状况出现异常波动，对公司经营业绩将产生一定影响。③税收优惠变化风险公司被认定为高新技术企业，享受高新技术企业所得税税收优惠，适用企业所得税税率为15%，同时还享受研究开发费用税前加计扣除等税收优惠，但如果相关税收政策发生变化，或者公司在经营过程中未能达到相关优惠条件，公司税负有可能增加，对公司未来经营业绩和现金流有不利影响。公司报告|首次覆盖报告请务必阅读正文之后的信息披露和免责申明22财务预测摘要资产负债表(百万元)201820192020E2021E2022E利润表(百万元)201820192020E2021E2022E货币资金265.55505.61897.571,409.642,334.46营业收入321.01557.72720.801,132.061,754.43应收票据及应收账款9.1214.7416.07(7.37)(11.42)营业成本34.2241.1068.48107.55166.67预付账款3.334.578.0412.6418.95营业税金及附加6.163.544.577.1811.12存货12.9723.2942.0755.73101.85营业费用62.4177.1775.68124.53201.76其他5.3016.4914.0113.8622.13管理费用44.4448.0961.2795.09145.62流动资产合计296.26564.70977.751,484.502,465.97研发费用33.6848.5672.08113.21175.44长期股权投资0.000.000.000.000.00财务费用(1.72)(1.71)(3.21)(5.28)(8.57)固定资产138.35150.64166.52202.49237.50资产减值损失1.07(0.02)(0.02)(0.02)(0.02)在建工程1.200.0036.0069.6071.76公允价值变动收益0.000.000.000.000.00无形资产8.9110.6610.269.859.45投资净收益0.756.973.073.393.55其他18.8917.6415.3617.2716.75其他(3.26)(16.20)(6.15)(6.79)(7.09)非流动资产合计167.35178.95228.14299.21335.45营业利润143.27350.21445.03693.201,065.95资产总计463.61743.651,205.901,783.712,801.42营业外收入0.000.680.520.300.38短期借款0.000.000.000.000.00营业外支出0.080.100.050.060.07应付票据及应付账款20.637.4379.0241.91128.64利润总额143.19350.79445.51693.451,066.26其他24.0559.8142.5867.8393.30所得税27.0652.8267.08104.42160.55流动负债合计44.6867.24121.61109.74221.93净利润116.13297.97378.42589.03905.71长期借款0.000.000.000.000.00少数股东损益(6.73)(7.55)(19.48)(26.45)(36.74)应付债券0.000.000.000.000.00归属于母公司净利润122.85305.52397.90615.48942.45其他14.1813.7012.9613.6213.43每股收益（元）1.022.543.315.127.84非流动负债合计14.1813.7012.9613.6213.43负债合计58.8780.95134.57123.35235.36少数股东权益6.333.77(15.71)(42.16)(78.90)主要财务比率201820192020E2021E2022E股本90.0090.00120.20120.20120.20成长能力资本公积139.69139.69139.69139.69139.69营业收入44.28%73.74%29.24%57.05%54.98%留存收益308.41568.93966.831,582.322,524.77营业利润52.90%144.45%27.07%55.77%53.77%其他(139.69)(139.69)(139.69)(139.69)(139.69)归属于母公司净利润49.47%148.68%30.24%54.68%53.12%股东权益合计404.74662.701,071.321,660.362,566.06获利能力负债和股东权益总计463.61743.651,205.901,783.712,801.42毛利率89.34%92.63%90.50%90.50%90.50%净利率38.27%54.78%55.20%54.37%53.72%ROE30.84%46.37%36.60%36.15%35.63%ROIC104.59%246.06%269.12%368.91%384.74%现金流量表(百万元)201820192020E2021E2022E偿债能力净利润118.39297.97397.90615.48942.45资产负债率12.70%10.88%11.16%6.92%8.40%折旧摊销8.1110.068.5210.8413.24净负债率-65.61%-76.30%-83.78%-84.90%-90.97%财务费用0.170.00(3.21)(5.28)(8.57)流动比率6.638.408.0413.5311.11投资损失(0.75)(6.97)(3.07)(3.39)(3.55)速动比率6.348.057.6913.0210.65营运资金变动2.9018.8334.81(7.80)55.88营运能力其它6.67(10.18)(19.48)(26.45)(36.74)应收账款周转率47.5146.7646.79260.18-186.74经营活动现金流135.50309.72415.47583.40962.71存货周转率21.0530.7622.0623.1522.27资本支出13.9023.3760.7479.3550.19总资产周转率0.750.920.740.760.77长期投资0.000.000.000.000.00每股指标（元）其他(52.31)(48.99)(117.67)(155.95)(96.64)每股收益1.022.543.315.127.84投资活动现金流(38.41)(25.62)(56.93)(76.61)(46.45)每股经营现金流1.132.583.464.858.01债权融资0.000.000.000.000.00每股净资产3.315.489.0414.1622.00股权融资1.721.7133.415.288.57估值比率其他(47.60)(45.74)0.000.000.00市盈率335.00134.71103.4366.8743.67筹资活动现金流(45.89)(44.03)33.415.288.57市净率103.3062.4637.8624.1715.56汇率变动影响0.000.000.000.000.00EV/EBITDA0.000.0089.3356.8036.17现金净增加额51.20240.06391.96512.07924.82EV/EBIT0.000.0091.0557.6936.62资料来源：公司公告，天风证券研究所公司报告|首次覆盖报告请务必阅读正文之后的信息披露和免责申明23分析师声明本报告署名分析师在此声明：我们具有中国证券业协会授予的证券投资咨询执业资格或相当的专业胜任能力，本报告所表述的所有观点均准确地反映了我们对标的证券和发行人的个人看法。我们所得报酬的任何部分不曾与，不与，也将不会与本报告中的具体投资建议或观点有直接或间接联系。一般声明除非另有规定，本报告中的所有材料版权均属天风证券股份有限公司（已获中国证监会许可的证券投资咨询业务资格）及其附属机构（以下统称“天风证券”）。未经天风证券事先书面授权，不得以任何方式修改、发送或者复制本报告及其所包含的材料、内容。所有本报告中使用的商标、服务标识及标记均为天风证券的商标、服务标识及标记。本报告是机密的，仅供我们的客户使用，天风证券不因收件人收到本报告而视其为天风证券的客户。本报告中的信息均来源于我们认为可靠的已公开资料，但天风证券对这些信息的准确性及完整性不作任何保证。本报告中的信息、意见等均仅供客户参考，不构成所述证券买卖的出价或征价邀请或要约。该等信息、意见并未考虑到获取本报告人员的具体投资目的、财务状况以及特定需求，在任何时候均不构成对任何人的个人推荐。客户应当对本报告中的信息和意见进行独立评估，并应同时考量各自的投资目的、财务状况和特定需求，必要时就法律、商业、财务、税收等方面咨询专家的意见。对依据或者使用本报告所造成的一切后果，天风证券及/或其关联人员均不承担任何法律责任。本报告所载的意见、评估及预测仅为本报告出具日的观点和判断。该等意见、评估及预测无需通知即可随时更改。过往的表现亦不应作为日后表现的预示和担保。在不同时期，天风证券可能会发出与本报告所载意见、评估及预测不一致的研究报告。天风证券的销售人员、交易人员以及其他专业人士可能会依据不同假设和标准、采用不同的分析方法而口头或书面发表与本报告意见及建议不一致的市场评论和/或交易观点。天风证券没有将此意见及建议向报告所有接收者进行更新的义务。天风证券的资产管理部门、自营部门以及其他投资业务部门可能独立做出与本报告中的意见或建议不一致的投资决策。特别声明在法律许可的情况下，天风证券可能会持有本报告中提及公司所发行的证券并进行交易，也可能为这些公司提供或争取提供投资银行、财务顾问和金融产品等各种金融服务。因此，投资者应当考虑到天风证券及/或其相关人员可能存在影响本报告观点客观性的潜在利益冲突，投资者请勿将本报告视为投资或其他决定的唯一参考依据。投资评级声明类别说明评级体系股票投资评级自报告日后的6个月内，相对同期沪深300指数的涨跌幅行业投资评级自报告日后的6个月内，相对同期沪深300指数的涨跌幅买入预期股价相对收益20%以上增持预期股价相对收益10%-20%持有预期股价相对收益-10%-10%卖出预期股价相对收益-10%以下强于大市预期行业指数涨幅5%以上中性预期行业指数涨幅-5%-5%弱于大市预期行业指数涨幅-5%以下天风证券研究北京武汉上海深圳北京市西城区佟麟阁路36号邮编：100031邮箱：research@tfzq.com湖北武汉市武昌区中南路99号保利广场A座37楼邮编：430071电话：(8627)-87618889传真：(8627)-87618863邮箱：research@tfzq.com上海市浦东新区兰花路333号333世纪大厦20楼邮编：201204电话：(8621)-68815388传真：(8621)-68812910邮箱：research@tfzq.com深圳市福田区益田路5033号平安金融中心71楼邮编：518000电话：(86755)-23915663传真：(86755)-82571995邮箱：research@tfzq.com","data":[{"id":"1","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"我国医美行业起步较晚，但发展迅速，2014-2018年复合增长23.6%","content_offset":["415","451"],"indicators":[{"indicator_name":"市场规模复合增长率","indicator_value":["23.6%","446","451"],"indicator_element":{"区域":["我国","415","417"],"行业":["医美","417","419"],"时间":["2014-2018年","432","442"]},"indicator_supplement":{"属性":""}}]},{"id":"2","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"2014-2018年收入CAGR约为25.7%","content_offset":["523","546"],"indicators":[{"indicator_name":"收入年复合增长率","indicator_value":["25.7%","541","546"],"indicator_element":{"项目":["非手术类医美项目","486","494"],"区域":["我国","514","516"],"时间":["2014-2018年","523","533"]},"indicator_supplement":{"属性":""}}]},{"id":"3","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"收入占比由2014年的28%提升至2018年的41%","content_offset":["547","573"],"indicators":[{"indicator_name":"收入占比","indicator_value":["28%","558","561"],"indicator_element":{"时间":["2014年","552","557"],"项目":["非手术类医美项目","486","494"],"区域":["我国","514","516"]},"indicator_supplement":{"属性":""}},{"indicator_name":"收入占比","indicator_value":["41%","570","573"],"indicator_element":{"时间":["2018年","564","569"],"项目":["非手术类医美项目","486","494"],"区域":["我国","514","516"]},"indicator_supplement":{"属性":""}}]},{"id":"4","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"非手术注射型医美项目占比约57.04%","content_offset":["640","659"],"indicators":[{"indicator_name":"项目占比","indicator_value":["57.04%","653","659"],"indicator_element":{"项目":["非手术类医美项目","11626","11634"],"区域":["我国","732","734"]},"indicator_supplement":{"属性":""}}]},{"id":"5","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"玻尿酸占注射型医美的比重约66.59%","content_offset":["660","679"],"indicators":[{"indicator_name":"项目占比","indicator_value":["约66.59%","672","679"],"indicator_element":{"项目":["玻尿酸","660","663"],"业务":["注射型医美","664","669"]},"indicator_supplement":{"属性":""}}]},{"id":"6","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"根据Frost&Sullivan预测，2021年我国将成为全球最大的医美服务市场，我国医美行业市场空间预计超过9000亿元","content_offset":["744","805"],"indicators":[{"indicator_name":"市场规模","indicator_value":["9000亿元","799","805"],"indicator_element":{"时间":["2021年","763","768"],"区域":["我国","768","770"],"行业":["医美","778","780"]},"indicator_supplement":{"属性":""}}]},{"id":"7","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"2017年至2019年，公司的综合毛利率从86.15%不断提升至92.63%","content_offset":["917","955"],"indicators":[{"indicator_name":"毛利率","indicator_value":["86.15%","938","944"],"indicator_element":{"时间":["2017年","917","922"],"公司":["爱美客","828","831"]},"indicator_supplement":{"属性":""}},{"indicator_name":"毛利率","indicator_value":["92.63%","949","955"],"indicator_element":{"时间":["2019年","923","928"],"公司":["爱美客","828","831"]},"indicator_supplement":{"属性":""}}]},{"id":"8","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"综合预计公司2020-2022年净利润3.98/6.15/9.42亿元","content_offset":["1192","1227"],"indicators":[{"indicator_name":"净利润","indicator_value":["3.98亿元","-1","-1"],"indicator_element":{"时间":["2020-2022年","1198","1208"],"公司":["爱美客","1819","1822"]},"indicator_supplement":{"属性":"预计"}},{"indicator_name":"净利润","indicator_value":["6.15亿元","-1","-1"],"indicator_element":{"时间":["2020-2022年","1198","1208"],"公司":["爱美客","1819","1822"]},"indicator_supplement":{"属性":"预计"}},{"indicator_name":"净利润","indicator_value":["9.42亿元","1221","1227"],"indicator_element":{"时间":["2020-2022年","1198","1208"],"公司":["爱美客","1819","1822"]},"indicator_supplement":{"属性":"预计"}}]},{"id":"9","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"对应2020/2021/2022年PE分别为103/67/44倍","content_offset":["1228","1260"],"indicators":[{"indicator_name":"PE估值","indicator_value":["103倍","-1","-1"],"indicator_element":{"时间":["2020","1230","1234"],"公司":["爱美客","1819","1822"]},"indicator_supplement":{"属性":"预计"}},{"indicator_name":"PE估值","indicator_value":["67倍","-1","-1"],"indicator_element":{"时间":["2021","1235","1239"],"公司":["爱美客","1819","1822"]},"indicator_supplement":{"属性":"预计"}},{"indicator_name":"PE估值","indicator_value":["44倍","1257","1260"],"indicator_element":{"时间":["2022年","1240","1245"],"公司":["爱美客","1819","1822"]},"indicator_supplement":{"属性":"预计"}}]},{"id":"10","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"全球医疗美容服务疗程数2011-2017年的年复合增长率为8.04%","content_offset":["10328","10362"],"indicators":[{"indicator_name":"医疗美容服务疗程数年复合增长率","indicator_value":["8.04%","10357","10362"],"indicator_element":{"时间":["2011-2017年","10339","10349"],"区域":["全球","10328","10330"]},"indicator_supplement":{"属性":""}}]},{"id":"11","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"2018年我国医美行业规模为1217亿元，同比增长22.6%","content_offset":["11053","11083"],"indicators":[{"indicator_name":"市场规模","indicator_value":["1217亿元","11067","11073"],"indicator_element":{"时间":["2018年","11053","11058"],"区域":["我国","11058","11060"],"行业":["医美","11060","11062"]},"indicator_supplement":{"属性":""}}]},{"id":"12","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"2018年我国医美行业规模为1217亿元，同比增长22.6%","content_offset":["11053","11083"],"indicators":[{"indicator_name":"市场规模同比","indicator_value":["22.60%","-1","-1"],"indicator_element":{"时间":["2018年","11053","11058"],"区域":["我国","11058","11060"],"行业":["医美","11060","11062"]},"indicator_supplement":{"属性":""}}]},{"id":"13","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"从医美项目数来看，2017年中国医美项目数达1020万例","content_offset":["11084","11112"],"indicators":[{"indicator_name":"项目数量","indicator_value":["1020万例","11106","11112"],"indicator_element":{"时间":["2017年","11093","11098"],"区域":["中国","11098","11100"],"行业":["医美","11085","11087"]},"indicator_supplement":{"属性":""}}]},{"id":"14","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"2014-2018年非手术类医美项目收入CAGR约为25.6%","content_offset":["11678","11709"],"indicators":[{"indicator_name":"收入年复合增长率","indicator_value":["约为25.6%","11702","11709"],"indicator_element":{"时间":["2014-2018年","11678","11688"],"区域":["我国","11669","11671"],"项目":["非手术类医美项目","11688","11696"]},"indicator_supplement":{"属性":""}}]},{"id":"15","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"而2014-2018年手术类医美项目收入CAGR约为22.3%","content_offset":["11710","11741"],"indicators":[{"indicator_name":"收入年复合增长率","indicator_value":["约为22.3%","11734","11741"],"indicator_element":{"时间":["2014-2018年","11711","11721"],"区域":["我国","11669","11671"],"项目":["手术类医美项目","11721","11728"]},"indicator_supplement":{"属性":""}}]},{"id":"16","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"非手术类医美项目收入占比由2014年的38%提升至2018年的41%","content_offset":["11742","11776"],"indicators":[{"indicator_name":"项目占比","indicator_value":["38%","11761","11764"],"indicator_element":{"时间":["2014年","11755","11760"],"区域":["我国","11669","11671"],"项目":["非手术类医美项目","11742","11750"]},"indicator_supplement":{"属性":""}},{"indicator_name":"项目占比","indicator_value":["41%","11773","11776"],"indicator_element":{"时间":["2018年","11767","11772"],"区域":["我国","11669","11671"],"项目":["非手术类医美项目","11742","11750"]},"indicator_supplement":{"属性":""}}]},{"id":"17","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"非手术案例数占比预计由2011年的59%提升至2018年的71%","content_offset":["11777","11809"],"indicators":[{"indicator_name":"项目占比","indicator_value":["59%","11794","11797"],"indicator_element":{"时间":["2011年","11788","11793"],"区域":["我国","12034","12036"],"项目":["非手术案例","11777","11782"]},"indicator_supplement":{"属性":""}},{"indicator_name":"项目占比","indicator_value":["71%","11806","11809"],"indicator_element":{"时间":["2018年","11800","11805"],"区域":["我国","12034","12036"],"项目":["非手术案例","11777","11782"]},"indicator_supplement":{"属性":""}}]},{"id":"18","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"根据Frost&Sullivan预测，2023年非手术类医美项目收入预计达到161亿元","content_offset":["11861","11904"],"indicators":[{"indicator_name":"收入","indicator_value":["161亿元","11899","11904"],"indicator_element":{"时间":["2023年","11880","11885"],"项目":["非手术类医美项目","11885","11893"]},"indicator_supplement":{"属性":""}}]},{"id":"19","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"收入占比将达到45%","content_offset":["11905","11915"],"indicators":[{"indicator_name":"收入占比","indicator_value":["45%","11912","11915"],"indicator_element":{"区域":["我国","12034","12036"],"时间":["2023年","11880","11885"],"项目":["非手术类医美项目","11885","11893"],"行业":["医美","11856","11858"]},"indicator_supplement":{"属性":""}}]},{"id":"20","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"而注射医美中，玻尿酸和肉毒素占比分别为66.59%和32.67%","content_offset":["12142","12174"],"indicators":[{"indicator_name":"项目占比","indicator_value":["66.59%","12161","12167"],"indicator_element":{"产品":["玻尿酸","12149","12152"],"区域":["我国","12983","12985"],"时间":["2018年","12175","12180"],"行业":["医美","12145","12147"]},"indicator_supplement":{"属性":""}},{"indicator_name":"项目占比","indicator_value":["32.67%","12168","12174"],"indicator_element":{"产品":["肉毒素","12153","12156"],"区域":["我国","12983","12985"],"时间":["2018年","12175","12180"],"行业":["医美","12145","12147"]},"indicator_supplement":{"属性":""}}]},{"id":"21","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"根据Frost&Sullivan，2014-2018年之间，中国医疗美容注射产品市场中，国产品牌销售收入增速较快，复合增长率为32.2%，高于同期进口品牌的18.7%","content_offset":["12315","12398"],"indicators":[{"indicator_name":"收入年复合增长率","indicator_value":["国产：区域","-1","-1"],"indicator_element":{"时间":["2014-2018年","12332","12342"],"区域":["国产","12359","12361"],"行业":["医疗美容","12347","12351"]},"indicator_supplement":{"属性":""}}]},{"id":"22","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"2019年25岁以下的医美消费者占比约54%","content_offset":["13038","13060"],"indicators":[{"indicator_name":"消费者构成","indicator_value":["约54%","13056","13060"],"indicator_element":{"时间":["2019年","13038","13043"],"行业":["医美","13049","13051"],"年龄分布":["25岁以下","13043","13048"],"区域":["我国","12983","12985"]},"indicator_supplement":{"属性":""}}]},{"id":"23","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"2019年30岁以上医美消费者占比已从2016年的13%提升至19%","content_offset":["13106","13140"],"indicators":[{"indicator_name":"消费者构成","indicator_value":["13%","13131","13134"],"indicator_element":{"时间":["2016年","13125","13130"],"行业":["医美","13116","13118"],"年龄分布":["30岁以下","-1","-1"],"区域":["我国","13008","13010"]},"indicator_supplement":{"属性":""}},{"indicator_name":"消费者构成","indicator_value":["19%","13137","13140"],"indicator_element":{"时间":["2019年","13106","13111"],"行业":["医美","13116","13118"],"年龄分布":["30岁以下","-1","-1"],"区域":["我国","13008","13010"]},"indicator_supplement":{"属性":""}}]},{"id":"24","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"从性别上看，2019年医美女性消费者数量占医美消费者总数的88.88%，女性消费者数量是男性消费者的8倍","content_offset":["13187","13239"],"indicators":[{"indicator_name":"消费者构成","indicator_value":["88.88%","13216","13222"],"indicator_element":{"时间":["2019年","13193","13198"],"行业":["医美","13198","13200"],"性别":["女性","13200","13202"]},"indicator_supplement":{"属性":""}}]},{"id":"25","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"2018年医美行业男性消费者平均客单价（7025元）是女性消费者平均客单价（2551元）的2.75倍","content_offset":["13254","13304"],"indicators":[{"indicator_name":"价格","indicator_value":["7025元","13274","13279"],"indicator_element":{"性别":["男性","13263","13265"],"时间":["2018年","13254","13259"],"行业":["医美","13259","13261"]},"indicator_supplement":{"属性":""}},{"indicator_name":"价格","indicator_value":["2551元","13292","13297"],"indicator_element":{"性别":["女性","13281","13283"],"时间":["2018年","13254","13259"],"行业":["医美","13259","13261"]},"indicator_supplement":{"属性":""}}]},{"id":"26","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"目前我国医美渗透率偏低，2018年我国医美诊疗次数为14.8次/千人","content_offset":["13443","13477"],"indicators":[{"indicator_name":"诊疗量","indicator_value":["14.8次/千人","13469","13477"],"indicator_element":{"时间":["2018年","13455","13460"],"区域":["我国","13445","13447"]},"indicator_supplement":{"属性":""}}]},{"id":"27","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"而从不同年龄段的渗透率来看，20-25岁的消费者中的医美渗透率约7.18%","content_offset":["13517","13554"],"indicators":[{"indicator_name":"渗透率","indicator_value":["7.18%","13549","13554"],"indicator_element":{"行业":["医美","13543","13545"],"年龄":["20-25岁","13531","13537"],"区域":["全国","13558","13560"]},"indicator_supplement":{"属性":""}}]},{"id":"28","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"远高于全国1.48%的渗透率，逼近韩国8.62%的渗透率","content_offset":["13555","13583"],"indicators":[{"indicator_name":"渗透率","indicator_value":["1.48%","13560","13565"],"indicator_element":{"区域":["全国","13558","13560"],"行业":["医美","13462","13464"]},"indicator_supplement":{"属性":""}},{"indicator_name":"渗透率","indicator_value":["8.62%","13574","13579"],"indicator_element":{"区域":["韩国","13572","13574"],"行业":["医美","13462","13464"]},"indicator_supplement":{"属性":""}}]},{"id":"29","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"根据Frost&Sullivan预测，2021年我国将成为全球最大的医美服务市场，2023年我国医美行业规模有望达到3601亿元","content_offset":["14173","14237"],"indicators":[{"indicator_name":"市场规模","indicator_value":["3601亿元","14231","14237"],"indicator_element":{"时间":["2023年","14214","14219"],"区域":["我国","14197","14199"],"行业":["医美","14207","14209"]},"indicator_supplement":{"属性":""}}]},{"id":"30","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"2018年我国医美消费水平为5893元/次，对标日本、巴西、美国、韩国平均52.85次/千人的诊疗次数，以及美国2018年12224元/次的消费水平","content_offset":["14274","14348"],"indicators":[{"indicator_name":"价格","indicator_value":["5893元/次","14288","14295"],"indicator_element":{"区域":["我国","14279","14281"],"时间":["2018年","14274","14279"],"行业":["医美","14281","14283"]},"indicator_supplement":{"属性":""}},{"indicator_name":"价格","indicator_value":["12224元/次","14335","14343"],"indicator_element":{"区域":["美国","14304","14306"],"时间":["2018年","14274","14279"],"行业":["医美","14281","14283"]},"indicator_supplement":{"属性":""}}]},{"id":"31","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"以2019年贡献最多销售收入的嗨体产品为例，以公司披露的单位成本24.72元/支倒算出透明质酸纳成本价大约为5.96元/支","content_offset":["15766","15827"],"indicators":[{"indicator_name":"成本","indicator_value":["24.72元/支","15798","15806"],"indicator_element":{"产品":["嗨体","15781","15783"],"时间":["2019年","15767","15772"]},"indicator_supplement":{"属性":""}},{"indicator_name":"成本","indicator_value":["5.96元/支","15820","15827"],"indicator_element":{"产品":["透明质酸钠","19462","19467"],"时间":["2019年","15767","15772"]},"indicator_supplement":{"属性":""}}]},{"id":"32","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"而嗨体的平均单价达到了352.61元/支","content_offset":["15828","15848"],"indicators":[{"indicator_name":"价格","indicator_value":["352.61元/支","15839","15848"],"indicator_element":{"时间":["2019年","15744","15749"],"产品":["嗨体","15829","15831"]},"indicator_supplement":{"属性":""}}]},{"id":"33","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"从2017年至2019年，公司的综合毛利率水平保持持续增长的态势，从86.15%不断提升至92.63%","content_offset":["16462","16513"],"indicators":[{"indicator_name":"毛利率","indicator_value":["86.15%","16496","16502"],"indicator_element":{"时间":["2017年","16463","16468"],"公司":["爱美客","16808","16811"]},"indicator_supplement":{"属性":""}},{"indicator_name":"毛利率","indicator_value":["92.63%","16507","16513"],"indicator_element":{"时间":["2019年","16469","16474"],"公司":["爱美客","16808","16811"]},"indicator_supplement":{"属性":""}}]},{"id":"34","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"其中嗨体和爱芙莱是公司的主打产品，2019年营收占比中嗨体为43.50%，爱芙莱39.27%，宝尼达以12.10%占比其次","content_offset":["17012","17073"],"indicators":[{"indicator_name":"营业收入占比","indicator_value":["43.50%","17042","17048"],"indicator_element":{"产品":["嗨体","17014","17016"],"时间":["2019年","17029","17034"],"公司":["爱美客","17894","17897"]},"indicator_supplement":{"属性":""}},{"indicator_name":"营业收入占比","indicator_value":["39.27%","17052","17058"],"indicator_element":{"产品":["爱芙莱","17017","17020"],"时间":["2019年","17029","17034"],"公司":["爱美客","17894","17897"]},"indicator_supplement":{"属性":""}},{"indicator_name":"营业收入占比","indicator_value":["12.10%","17063","17069"],"indicator_element":{"产品":["宝尼达","17059","17062"],"时间":["2019年","17029","17034"],"公司":["爱美客","17894","17897"]},"indicator_supplement":{"属性":""}}]},{"id":"35","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"直销模式下嗨体平均单价从2017年286.83元上升到2019年的354.19元","content_offset":["18586","18626"],"indicators":[{"indicator_name":"价格","indicator_value":["286.83元","18603","18610"],"indicator_element":{"时间":["2017年","18598","18603"],"产品":["嗨体","18591","18593"]},"indicator_supplement":{"属性":""}},{"indicator_name":"价格","indicator_value":["354.19元","18619","18626"],"indicator_element":{"时间":["2019年","18613","18618"],"产品":["嗨体","18591","18593"]},"indicator_supplement":{"属性":""}}]},{"id":"36","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"销量从8.57万支上升到36.08万支","content_offset":["18627","18646"],"indicators":[{"indicator_name":"销量","indicator_value":["8.57万支","18630","18636"],"indicator_element":{"时间":["2017年","18598","18603"],"产品":["嗨体","18532","18534"]},"indicator_supplement":{"属性":""}},{"indicator_name":"销量","indicator_value":["36.08万支","18639","18646"],"indicator_element":{"时间":["2019年","18613","18618"],"产品":["嗨体","18532","18534"]},"indicator_supplement":{"属性":""}}]},{"id":"37","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"经销模式下嗨体从2017年的280.44元上升到2019年的269.03元","content_offset":["18647","18684"],"indicators":[{"indicator_name":"价格","indicator_value":["280.44元","18661","18668"],"indicator_element":{"时间":["2017年","18655","18660"],"产品":["嗨体","18652","18654"]},"indicator_supplement":{"属性":""}},{"indicator_name":"价格","indicator_value":["269.03元","18677","18684"],"indicator_element":{"时间":["2019年","18671","18676"],"产品":["嗨体","18652","18654"]},"indicator_supplement":{"属性":""}}]},{"id":"38","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"销量从3.47万支上升到32.72万支","content_offset":["18685","18704"],"indicators":[{"indicator_name":"销量","indicator_value":["3.47万支","18688","18694"],"indicator_element":{"时间":["2017年","18598","18603"],"产品":["嗨体","18591","18593"]},"indicator_supplement":{"属性":""}},{"indicator_name":"销量","indicator_value":["32.72万支","18697","18704"],"indicator_element":{"时间":["2019年","18613","18618"],"产品":["嗨体","18591","18593"]},"indicator_supplement":{"属性":""}}]},{"id":"39","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"而公司直销渠道在2019年占比64.08%","content_offset":["18738","18759"],"indicators":[{"indicator_name":"渠道占比","indicator_value":["64.08%","18753","18759"],"indicator_element":{"时间":["2019年","18746","18751"],"公司":["爱美客","18870","18873"]},"indicator_supplement":{"属性":""}}]},{"id":"40","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"已与超过2000家客户建立合作关系","content_offset":["18760","18777"],"indicators":[{"indicator_name":"客户规模","indicator_value":["2000家","18764","18769"],"indicator_element":{"时间":["2019年","18671","18676"],"公司":["爱美客","18870","18873"]},"indicator_supplement":{"属性":""}}]},{"id":"41","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"由于公司玻尿酸产品占公司营收比几乎接近100%，其他主营业务占比仅为0.15%","content_offset":["18988","19027"],"indicators":[{"indicator_name":"营业收入占比","indicator_value":["接近100%","19005","19011"],"indicator_element":{"产品":["玻尿酸","18992","18995"],"公司":["爱美客","19334","19337"]},"indicator_supplement":{"属性":""}},{"indicator_name":"营业收入占比","indicator_value":["0.15%","19022","19027"],"indicator_element":{"产品":["其他主营业务","19012","19018"],"公司":["爱美客","19334","19337"]},"indicator_supplement":{"属性":""}}]},{"id":"42","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"以公司营收数据和销量数据算出公司产品综合的平均单价，从2017年338.59元/支稳步上升到2019年383.13元/支","content_offset":["19028","19088"],"indicators":[{"indicator_name":"价格","indicator_value":["338.59元/支","19060","19069"],"indicator_element":{"时间":["2017年","19055","19060"],"产品":["玻尿酸","18938","18941"],"公司":["爱美客","19334","19337"]},"indicator_supplement":{"属性":""}},{"indicator_name":"价格","indicator_value":["383.13元/支","19079","19088"],"indicator_element":{"时间":["2019年","19074","19079"],"产品":["玻尿酸","18938","18941"],"公司":["爱美客","19334","19337"]},"indicator_supplement":{"属性":""}}]},{"id":"43","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"选取华熙生物注射用透明质酸中销售占比最高的润百颜和润致为代表，计算出其平均售价从2016年的425.85元/ml下降到2019年前3个月的290.44元/ml","content_offset":["19089","19168"],"indicators":[{"indicator_name":"价格","indicator_value":["425.85元/ml","19135","19145"],"indicator_element":{"时间":["2016年","19129","19134"],"公司":["华熙生物","19091","19095"],"产品":["注射用透明质酸","19095","19102"]},"indicator_supplement":{"属性":""}},{"indicator_name":"价格","indicator_value":["290.44元/ml","19158","19168"],"indicator_element":{"时间":["2019年前3个月","19148","19157"],"公司":["华熙生物","19091","19095"],"产品":["注射用透明质酸","19095","19102"]},"indicator_supplement":{"属性":""}}]},{"id":"44","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"昊海生科的业务布局较广，其在财报中对各项业务进行了单独数据披露，选取其中玻尿酸的相关数据，粗略以营收数据和销量数据计算出公司玻尿酸产品的平均单价，从2017年290.55元/支下降到2019年268.65元/支","content_offset":["19169","19274"],"indicators":[{"indicator_name":"价格","indicator_value":["290.55元/支","19248","19257"],"indicator_element":{"时间":["2017年","19243","19248"],"公司":["昊海生科","19169","19173"],"产品":["玻尿酸","19205","19208"]},"indicator_supplement":{"属性":""}},{"indicator_name":"价格","indicator_value":["268.65元/支","19265","19274"],"indicator_element":{"时间":["2019年","19260","19265"],"公司":["昊海生科","19169","19173"],"产品":["玻尿酸","19205","19208"]},"indicator_supplement":{"属性":""}}]},{"id":"45","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"2017/2018/2019年公司营收分别为2.22/3.21/5.58亿元，同比增速为58.09%/44.28%/73.74%","content_offset":["19473","19537"],"indicators":[{"indicator_name":"营业收入","indicator_value":["","19473","19473"],"indicator_element":{"时间":["2017","19473","19477"],"公司":["爱美客","19920","19923"],"产品":["透明质酸钠","19462","19467"]},"indicator_supplement":{"属性":""}},{"indicator_name":"营业收入","indicator_value":["","19473","19473"],"indicator_element":{"时间":["2018","19478","19482"],"公司":["爱美客","19920","19923"],"产品":["透明质酸钠","19462","19467"]},"indicator_supplement":{"属性":""}},{"indicator_name":"营业收入","indicator_value":["5.58亿元","19505","19511"],"indicator_element":{"时间":["2019年","19483","19488"],"公司":["爱美客","19920","19923"],"产品":["透明质酸钠","19462","19467"]},"indicator_supplement":{"属性":""}}]},{"id":"46","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"2017/2018/2019年公司营收分别为2.22/3.21/5.58亿元，同比增速为58.09%/44.28%/73.74%","content_offset":["19473","19537"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["58.09%","19517","19523"],"indicator_element":{"时间":["2017","19473","19477"],"公司":["爱美客","19920","19923"],"产品":["透明质酸钠","19462","19467"]},"indicator_supplement":{"属性":""}},{"indicator_name":"营业收入同比","indicator_value":["44.28%","19524","19530"],"indicator_element":{"时间":["2018","19478","19482"],"公司":["爱美客","19920","19923"],"产品":["透明质酸钠","19462","19467"]},"indicator_supplement":{"属性":""}},{"indicator_name":"营业收入同比","indicator_value":["73.74%","19531","19537"],"indicator_element":{"时间":["2019年","19483","19488"],"公司":["爱美客","19920","19923"],"产品":["透明质酸钠","19462","19467"]},"indicator_supplement":{"属性":""}}]},{"id":"47","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"营收高速增长，近三年增速维持在40%以上","content_offset":["19538","19558"],"indicators":[{"indicator_name":"营业收入复合增长率","indicator_value":["40%以上","19553","19558"],"indicator_element":{"公司":["爱美客","19920","19923"],"产品":["透明质酸钠","19462","19467"],"时间":["近三年","19545","19548"]},"indicator_supplement":{"属性":""}}]},{"id":"48","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"2020H1营收为2.42亿，同比增长0.72%","content_offset":["19559","19583"],"indicators":[{"indicator_name":"营业收入","indicator_value":["2.42亿元","-1","-1"],"indicator_element":{"公司":["爱美客","19920","19923"],"产品":["透明质酸钠","19462","19467"],"时间":["2020H1","19559","19565"]},"indicator_supplement":{"属性":""}}]},{"id":"49","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"2020H1营收为2.42亿，同比增长0.72%","content_offset":["19559","19583"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["0.72%","19578","19583"],"indicator_element":{"公司":["爱美客","19920","19923"],"产品":["透明质酸钠","19462","19467"],"时间":["2020H1","19559","19565"]},"indicator_supplement":{"属性":""}}]},{"id":"50","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"公司营业收入主要来自爱芙莱、宝尼达、嗨体等注射类透明质酸钠相关产品的销售，上述产品销售收入占主营业务收入的比例在近三年均超过95%","content_offset":["19606","19671"],"indicators":[{"indicator_name":"收入占比","indicator_value":["超过95%","19666","19671"],"indicator_element":{"产品":["注射类透明质酸钠相关产品","19627","19639"],"时间":["近三年","19662","19665"],"公司":["爱美客","19920","19923"]},"indicator_supplement":{"属性":""}}]},{"id":"51","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"公司直销模式下客户分为非公立医疗机构和公立医院两类，其中从非公立医疗机构取得的收入占直销收入的比例超过95%","content_offset":["20252","20306"],"indicators":[{"indicator_name":"收入占比","indicator_value":["超过95%","20301","20306"],"indicator_element":{"渠道":["非公立医疗机构","20263","20270"],"公司":["爱美客","20158","20161"]},"indicator_supplement":{"属性":""}}]},{"id":"52","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"近三年经销收入占比逐年提升，在2019年达到35.92%","content_offset":["20372","20400"],"indicators":[{"indicator_name":"收入占比","indicator_value":["35.92%","20394","20400"],"indicator_element":{"渠道":["经销","20375","20377"],"时间":["2019年","20387","20392"],"公司":["爱美客","20405","20408"]},"indicator_supplement":{"属性":""}}]},{"id":"53","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"2017/2018/2019/2020H1公司综合毛利率分别为86.15%/89.34%/92.63%/90.22%","content_offset":["20477","20535"],"indicators":[{"indicator_name":"毛利率","indicator_value":["86.15%","20508","20514"],"indicator_element":{"时间":["2017","20477","20481"],"公司":["爱美客","20405","20408"]},"indicator_supplement":{"属性":""}},{"indicator_name":"毛利率","indicator_value":["89.34%","20515","20521"],"indicator_element":{"时间":["2018","20482","20486"],"公司":["爱美客","20405","20408"]},"indicator_supplement":{"属性":""}},{"indicator_name":"毛利率","indicator_value":["92.63%","20522","20528"],"indicator_element":{"时间":["2019","20487","20491"],"公司":["爱美客","20405","20408"]},"indicator_supplement":{"属性":""}},{"indicator_name":"毛利率","indicator_value":["90.22%","20529","20535"],"indicator_element":{"时间":["2020H1","20492","20498"],"公司":["爱美客","20405","20408"]},"indicator_supplement":{"属性":""}}]},{"id":"54","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"2019年主要产品毛利率均在90%以上","content_offset":["20457","20476"],"indicators":[{"indicator_name":"毛利率","indicator_value":["90%以上","20471","20476"],"indicator_element":{"公司":["爱美客","20405","20408"],"时间":["2019年","20457","20462"]},"indicator_supplement":{"属性":""}}]},{"id":"55","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"2017/2018/2019公司期间费用率分别为42.88%/43.24%/30.86%","content_offset":["21225","21269"],"indicators":[{"indicator_name":"费用率","indicator_value":["42.88%","21249","21255"],"indicator_element":{"时间":["2017","21225","21229"],"公司":["爱美客","21387","21390"]},"indicator_supplement":{"属性":""}},{"indicator_name":"费用率","indicator_value":["43.24%","21256","21262"],"indicator_element":{"时间":["2018","21230","21234"],"公司":["爱美客","21387","21390"]},"indicator_supplement":{"属性":""}},{"indicator_name":"费用率","indicator_value":["30.86%","21263","21269"],"indicator_element":{"时间":["2019","21235","21239"],"公司":["爱美客","21387","21390"]},"indicator_supplement":{"属性":""}}]},{"id":"56","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"2020H1期间费用率进一步下降到24.27%","content_offset":["21302","21325"],"indicators":[{"indicator_name":"费用率","indicator_value":["24.27%","21319","21325"],"indicator_element":{"公司":["爱美客","21387","21390"],"时间":["2020H1","21302","21308"]},"indicator_supplement":{"属性":""}}]},{"id":"57","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"2017/2018/2019年公司归母净利润分别为0.82/1.23/3.06亿元，同比增速为53.99%/49.47%/148.68%","content_offset":["21488","21556"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["","21488","21488"],"indicator_element":{"时间":["2017","21488","21492"],"公司":["爱美客","21408","21411"]},"indicator_supplement":{"属性":""}},{"indicator_name":"归母净利润","indicator_value":["","21488","21488"],"indicator_element":{"时间":["2018","21493","21497"],"公司":["爱美客","21408","21411"]},"indicator_supplement":{"属性":""}},{"indicator_name":"归母净利润","indicator_value":["3.06亿元","21523","21529"],"indicator_element":{"时间":["2019年","21498","21503"],"公司":["爱美客","21408","21411"]},"indicator_supplement":{"属性":""}}]},{"id":"58","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"2017/2018/2019年公司归母净利润分别为0.82/1.23/3.06亿元，同比增速为53.99%/49.47%/148.68%","content_offset":["21488","21556"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["53.99%","21535","21541"],"indicator_element":{"时间":["2017","21488","21492"],"公司":["爱美客","21408","21411"]},"indicator_supplement":{"属性":""}},{"indicator_name":"归母净利润同比","indicator_value":["49.47%","21542","21548"],"indicator_element":{"时间":["2018","21493","21497"],"公司":["爱美客","21408","21411"]},"indicator_supplement":{"属性":""}},{"indicator_name":"归母净利润同比","indicator_value":["148.68%","21549","21556"],"indicator_element":{"时间":["2019年","21498","21503"],"公司":["爱美客","21408","21411"]},"indicator_supplement":{"属性":""}}]},{"id":"59","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"2020H1归母净利润为1.48亿元，同比增速为14.59%","content_offset":["21557","21587"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["1.48亿元","21569","21575"],"indicator_element":{"公司":["爱美客","21750","21753"]},"indicator_supplement":{"属性":""}}]},{"id":"60","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"2020H1归母净利润为1.48亿元，同比增速为14.59%","content_offset":["21557","21587"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["14.59%","21581","21587"],"indicator_element":{"公司":["爱美客","21750","21753"]},"indicator_supplement":{"属性":""}}]},{"id":"61","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"2017/2018/2019年公司经营活动现金流净额分别为0.84/1.35/3.1亿元","content_offset":["22368","22412"],"indicators":[{"indicator_name":"经营性现金流","indicator_value":["","22368","22368"],"indicator_element":{"时间":["2017","22368","22372"],"公司":["爱美客","22617","22620"]},"indicator_supplement":{"属性":""}},{"indicator_name":"经营性现金流","indicator_value":["","22368","22368"],"indicator_element":{"时间":["2018","22373","22377"],"公司":["爱美客","22617","22620"]},"indicator_supplement":{"属性":""}},{"indicator_name":"经营性现金流","indicator_value":["3.1亿元","22407","22412"],"indicator_element":{"时间":["2019年","22378","22383"],"公司":["爱美客","22617","22620"]},"indicator_supplement":{"属性":""}}]},{"id":"62","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"公司2020H1投资活动现金流相比往年流出规模较大，上半年为-3.04亿","content_offset":["22505","22541"],"indicators":[{"indicator_name":"投资活动产生的现金流量","indicator_value":["-3.04亿","22535","22541"],"indicator_element":{"公司":["爱美客","22617","22620"],"时间":["上半年","22531","22534"]},"indicator_supplement":{"属性":""}}]},{"id":"63","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"公司嗨体是市场唯一获批颈纹改善三类医械产品，近几年能保持高增速，预计2020/2021/2022年嗨体销量增长60%/70%/60%","content_offset":["23959","24025"],"indicators":[{"indicator_name":"销量","indicator_value":["60%","24014","24017"],"indicator_element":{"时间":["2020","23993","23997"],"产品":["嗨体","23961","23963"],"公司":["爱美客","23894","23897"]},"indicator_supplement":{"属性":""}},{"indicator_name":"销量","indicator_value":["70%","24018","24021"],"indicator_element":{"时间":["2021","23998","24002"],"产品":["嗨体","23961","23963"],"公司":["爱美客","23894","23897"]},"indicator_supplement":{"属性":""}},{"indicator_name":"销量","indicator_value":["60%","24014","24017"],"indicator_element":{"时间":["2022年","24003","24008"],"产品":["嗨体","23961","23963"],"公司":["爱美客","23894","23897"]},"indicator_supplement":{"属性":""}}]},{"id":"64","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"植入医疗器械生产线二期建设项目预计三年大成后产能分别为爱芙莱127.87万支、嗨体220.87万支、逸美10.33万支、宝尼达1.64万支","content_offset":["24036","24105"],"indicators":[{"indicator_name":"产能","indicator_value":["127.87万支","24066","24074"],"indicator_element":{"产品":["爱芙莱","24063","24066"],"时间":["三年","24053","24055"],"行业":["医疗器械生产","24038","24044"]},"indicator_supplement":{"属性":"预计"}},{"indicator_name":"产能","indicator_value":["220.87万支","24077","24085"],"indicator_element":{"产品":["嗨体","24075","24077"],"时间":["三年","24053","24055"],"行业":["医疗器械生产","24038","24044"]},"indicator_supplement":{"属性":"预计"}},{"indicator_name":"产能","indicator_value":["10.33万支","24088","24095"],"indicator_element":{"产品":["逸美","24086","24088"],"时间":["三年","24053","24055"],"行业":["医疗器械生产","24038","24044"]},"indicator_supplement":{"属性":"预计"}},{"indicator_name":"产能","indicator_value":["1.64万支","24099","24105"],"indicator_element":{"产品":["宝尼达","24096","24099"],"时间":["三年","24053","24055"],"行业":["医疗器械生产","24038","24044"]},"indicator_supplement":{"属性":"预计"}}]},{"id":"65","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"综合预计公司2020-2022年净利润3.98/6.15/9.42亿元","content_offset":["1192","1227"],"indicators":[{"indicator_name":"净利润","indicator_value":["","1192","1192"],"indicator_element":{"时间":["2020-2022年","1198","1208"],"公司":["爱美客","1819","1822"]},"indicator_supplement":{"属性":"预计"}},{"indicator_name":"净利润","indicator_value":["","1192","1192"],"indicator_element":{"时间":["2020-2022年","1198","1208"],"公司":["爱美客","1819","1822"]},"indicator_supplement":{"属性":"预计"}},{"indicator_name":"净利润","indicator_value":["9.42亿元","1221","1227"],"indicator_element":{"时间":["2020-2022年","1198","1208"],"公司":["爱美客","1819","1822"]},"indicator_supplement":{"属性":"预计"}}]},{"id":"66","source_document":"爱美客（300896）：差异化铸就壁垒，专业倾斜医美龙头面板.pdf","content":"对应2020/2021/2022年PE分别为103/67/44倍","content_offset":["1228","1260"],"indicators":[{"indicator_name":"PE估值","indicator_value":["103倍","-1","-1"],"indicator_element":{"时间":["2020","1230","1234"],"公司":["爱美客","1819","1822"]},"indicator_supplement":{"属性":""}},{"indicator_name":"PE估值","indicator_value":["67倍","-1","-1"],"indicator_element":{"时间":["2021","1235","1239"],"公司":["爱美客","1819","1822"]},"indicator_supplement":{"属性":""}},{"indicator_name":"PE估值","indicator_value":["44倍","1257","1260"],"indicator_element":{"时间":["2022年","1240","1245"],"公司":["爱美客","1819","1822"]},"indicator_supplement":{"属性":""}}]}]}